#United States #Atlanta #KYGEVVI®|Thymidine Kinase 2|UCB

UCB's KYGEVVI® Shows Significant Promise for TK2d Patients

In a remarkable development for patients affected by thymidine kinase 2 deficiency (TK2d), UCB, a renowned biopharmaceutical company, announced the publication of vital research in the journal Brain Communications. These studies evaluate the first approved treatment, KYGEVVI® (doxecitine and doxribtimine), demonstrating significant improvements in patient survival and functional outcomes.

Overview of TK2d

Thymidine kinase 2 deficiency is an ultra-rare mitochondrial disorder, typically manifesting in infancy or early childhood. It is characterized by progressive muscle weakness and life-threatening complications, which if left untreated, can result in early mortality. Before the approval of KYGEVVI®, there were no effective treatment options available beyond supportive care. This highlights the urgency for effective diagnosis and intervention, particularly during the early stages of the disease.

Key Findings from UCB's Studies

The published manuscripts present compelling evidence regarding the efficacy and safety of KYGEVVI® in treating TK2d:
1. Improved Patient Outcomes: In a cohort of patients whose symptoms began before the age of 12, treatment with KYGEVVI® resulted in a 92% to 94% reduction in mortality compared to untreated individuals. Notably, the average survival time for treated patients extended to 29.2 years, significantly longer than the 14.4 years observed in those who did not receive treatment.
2. Functional Recovery: Post-treatment assessments revealed that 75% of patients gained back at least one motor skill, highlighting the therapeutic potential of KYGEVVI® in reversing some of the debilitating effects of TK2d.
3. Safety Profile: The treatment was generally well tolerated, although gastrointestinal side effects like diarrhea were noted, requiring dose adjustments for some patients.

The Importance of Early Diagnosis

UCB's research further emphasizes the critical need for early diagnosis of TK2d. The studies revealed alarming data on untreated patients, indicating a severe progression of the disease and an increased risk of premature death. Alarmingly, more than half (56.4%) of patients with an early symptom onset succumbed to the illness before the age of 2. The importance of genetic testing for accurate diagnosis is underscored in these findings, as timely treatment can vastly improve outcomes for patients and families affected by this rare disorder.

Expert Insights

Caterina Garone, Associate Professor of Medical Genetics at the University of Bologna and co-author of the studies, stresses the potential devastation of TK2d on both patients and their families, particularly when left untreated. The integrated findings published in Brain Communications serve as a crucial reminder of the disease’s burden and the life-altering benefits that timely intervention can provide.

Dr. Michio Hirano, Chief of the Division of Neuromuscular Medicine at Columbia University, also remarked on the significance of these findings, calling it a substantial advancement for patients suffering from this genetic disorder.

Moving Forward

Since its approval by the FDA in November 2025 and the EMA in March 2026, KYGEVVI® has become the first medication available for treating early-onset TK2d. As UCB's Chief Medical Officer, Donatello Crocetta, stated, the company remains committed to improving diagnosis and providing therapeutic options that meet the urgent needs of the TK2d community.

The studies published by UCB not only offer hope for those affected by TK2d but also pave the way for further research into effective treatments for rare genetic disorders. As we look into the future, the promise of more innovative solutions beckons for patients battling with challenges similar to those posed by TK2d.